Objective: Cigarette smoking impairs peripheral endothelium-dependent vasodilatation and acute tissue plasminogen activator (t-PA) release in man. The aim of the study was to determine if this endothelial dysfunction is, in part, mediated by the effects of nicotine. Methods: Blood flow and plasma fibrinolytic factors were measured in both forearms of eight healthy male non-smokers during unilateral brachial artery infusion of the endothelium-dependent vasodilator, substance P (2 to 8 pmol / min). Endothelium-independent vasodilatation was assessed using intra-arterial infusion of sodium nitroprusside (2 to 8 mg / min). Subjects attended after 7 days treatment with transdermal nicotine or placebo in a double blind randomised crossover design. Results: Plasma cotinine concentrations rose from 0.460.1 (placebo) to 125625 ng / ml during nicotine administration (P,0.001). On both treatment days, substance P caused dosedependent increases in blood flow and plasma t-PA antigen and activity concentrations (P,0.001 for all) but had no effect on plasma plasminogen activator inhibitor type 1 (PAI-1) concentrations. Compared with placebo, nicotine administration increased the substance-Pinduced release of t-PA antigen and activity (P,0.05 for both) without an effect on endothelium-dependent or -independent vasodilatation. Conclusions: Short-term transdermal nicotine treatment does not affect endothelium-dependent vasomotion but does increase substance-P-induced t-PA release in vivo in man. This suggests that nicotine administration alters specific aspects of endothelial function and enhances the acute endogenous fibrinolytic capacity in vivo. The long-term effects of nicotine exposure, including the potential to cause depletion of endothelial t-PA stores, now needs to be assessed.
Introduction
cular tone is important, this may not reflect other crucial aspects of endothelial function such as haemostasis and Cigarette smoking is a major risk factor for cardiovascufibrinolysis. lar disease [1] and is associated with acute coronary Focal areas of endothelial denudation and thrombus thrombosis and sudden cardiac death [2] . The mechanisms deposition are a common finding on the surface of underlying these associations are unknown although previatheromatous plaques and usually remain subclinical. ous studies have demonstrated that regular smokers have However, in the presence of an imbalance in the haemosimpaired endothelium-dependent vasodilatation in both the tatic or fibrinolytic system such microthrombi may propperipheral [3] and coronary circulations [4] . Endothelial agate ultimately leading to arterial occlusion [5] . The dysfunction may, therefore, contribute to the thrombotic degradation and clearance of intravascular thrombus is consequences and complications of cigarette smoking.
regulated by tissue-type plasminogen activator (t-PA), a However, whilst endothelium-dependent regulation of vasserine protease that is released from the endothelial cells through the translocation of a dynamic intracellular storage pool. The efficacy of plasminogen activation and fibrin the acute release of t-PA and its subsequent inhibition (Portex Ltd., Kent, UK) and patency was maintained by through formation of complexes with its inhibitor, plasinfusion of saline (0.9% Baxter Healthcare Ltd., Norfolk, minogen activator inhibitor type 1 (PAI-1). Thus, through UK) via an IVAC P1000 syringe pump (IVAC Ltd., the acute release of t-PA, endothelial function may have a Basingstoke, UK). The total rate of intra-arterial infusions central role in the regulation of intravascular thrombus was maintained constant throughout all studies at 1 ml / formation and, if impaired, may contribute to the pathomin. Pharmaceutical grade substance P (Clinalfa AG, genesis of acute myocardial infarction and sudden cardiac Laufelfingen, Switzerland) and sodium nitroprusside death. We have previously described an in vivo model to (Faulding DBL Pharmaceutical, Leamington, UK) were assess the acute release of t-PA from the endothelium in administered following dissolution in saline. the forearm vascular bed of man [6] . Using this approach, we have been able to demonstrate that cigarette smoking markedly impairs the acute peripheral release of t-PA [7] .
2.3. Measurements However, the mechanism of this attenuated endothelial response was not established.
Blood flow was measured in both forearms by venous Nicotine is a major component of cigarette smoke that is occlusion plethysmography using mercury-in-silastic strain rapidly absorbed following inhalation. Nicotine replacegauges applied to the widest part of the forearm [13] . ment therapy (NRT), either as a gum or patch preparations, During measurement periods, the hands were excluded has become freely available for over-the-counter sale as a from the circulation by rapid inflation of the wrist cuffs to medication to assist in smoking cessation. A number of a pressure of 220 mmHg using E20 Rapid Cuff Inflators reports of thrombotic cardiovascular events have been (D.E. Hokanson, Washington, USA). Upper arm cuffs were reported amongst individuals regularly using NRT [8] . Cell inflated intermittently to 40 mmHg for 10 s in every 15 s culture and in vivo animal studies [9] [10] [11] [12] Computers, Cupertino, USA). Calibration was achieved vasodilatation and whether it affects the endogenous using the internal standard of the plethysmograph. fibrinolytic capacity in the peripheral circulation of man.
Blood pressure was monitored in the non-infused arm at intervals throughout each study with a semi-automated non-invasive oscillometric sphygmomanometer (Takeda UA 751, Takeda Medical, Tokyo, Japan).
Methods
Venous cannulae (17-gauge) were inserted into the deep large subcutaneous veins of the antecubital fossae of both 2.1. Subjects arms. Blood (10 ml) was withdrawn simultaneously from each arm and collected into acidified buffered citrate Eight healthy male non-smokers participated in the( Biopool Stabilyte, Umea, Sweden for t-PA assays) and study which was undertaken with the approval of the localc itrate (Monovette, Sarstedt, Numbrecht, Germany for research ethics committee and in accordance with the PAI-1 assays) tubes, and kept on ice before being cenDeclaration of Helsinki. The written informed consent of trifuged at 20003g for 30 min at 48C. Platelet-free plasma each subject was obtained before entry into the study.
was decanted and stored at 2808C before assay. Plasma None of the subjects received vasoactive or nonsteroidal PAI-1 antigen and t-PA antigen were determined as previanti-inflammatory drugs in the week before the study, and ously described [6, 7] using ELISA (Coaliza PAI-1 and all abstained from alcohol for 24 h before, and from food t-PA, Chromogenix AB) and t-PA activity was measured and caffeine-containing drinks on the day of, the study. All using a photometric method (Coaset t-PA, Chromogenix studies were performed in a quiet, temperature-controlled AB). Haematocrit was determined by an Ac T Counter room maintained at 22-258C.
(Coulter Corporation, Miami, USA) at baseline and during infusion of 8 pmol / min of substance P. Plasma lipid 2.2. Intra-arterial drug administration fractions were measured by an enzymatic colorimetric method (Boehring Mannheim GmbH Diagnostica, GerThe brachial artery of the nondominant arm was cannumany). LDL cholesterol was derived according to the lated with a 27-standard wire gauge steel needle (Cooper's method of Friedewald et al. [14] . Plasma cotinine was Needle Works Ltd., Sheffield, UK) under local anaesthesia. determined by gas-liquid chromatography as previously The cannula was attached to a 16-gauge epidural catheter described [15] . 
Study design
Estimated net release of t-PA activity and antigen was previously defined [6, 7] as the product of the infused Subjects attended on two occasions separated by at least forearm plasma flow (based on the mean haematocrit, Hct, 1 week. Topical nicotine or placebo patches were applied and the infused forearm blood flow, FBF) and the confor 7 days prior to the study day in a double blind centration difference between the infused ([ Inf Non-inf administered in a similar manner such that double blinding was maintained. On the study day, subjects attended fasted Data were examined, where appropriate, by two-way and rested recumbent throughout. Strain gauges and cuffs analysis of variance (ANOVA) with repeated measures and were applied, and the brachial artery of the non-dominant two-tailed paired Student's t-test using Excel v5.0 (Miarm was cannulated as described above. Forearm blood crosoft). All results are expressed as mean6standard error flow was measured every 10 min. Saline was infused for of the mean (S.E.M.). Statistical significance was taken at the first 30 min to allow time for equilibration with the the 5% level. final measurement taken as the baseline blood flow, time 0. Thereafter, the subjects received intra-arterial substance P at 2, 4 and 8 pmol / min for 10 min at each dose. After a 30-min washout of saline infusion, the subjects received 3. Results also an intra-arterial infusion of sodium nitroprusside (SNP) at 2, 4 and 8 mg / min for 10 min at each dose to All subjects were normotensive with a normal serum assess endothelium-independent vasodilatation. Tissuelipid profile and plasma glucose concentration (Table 1) . plasminogen activator was measured at baseline and with Nicotine administration significantly increased plasma each dose of substance P. Plasminogen activator inhibitor cotinine levels from 0.460.1 to 125625 ng / ml (P,0.001, was measured at baseline and at substance P 8 pmol / min. paired t-test). There were no significant changes in blood In this model, SNP infusion does not affect fibrinolytic pressure, heart rate, haematocrit or blood flow in the variables [6, 16] and was, therefore, not measured. The non-infused forearm during each of the study days (Table order of the substance P and SNP infusions was random-2). During nicotine administration, the heart rate and the ised between subjects in each study but remained constant non-infused and infused forearm blood flows were confor each subject. Plasma cotinine concentrations were sistently higher than during placebo (Table 2) . Two measured at baseline on each study day.
subjects were unable to tolerate the higher dose of nicotine and returned to the 17.5 mg nicotine patch for the remainder of the 7 days.
Data analysis and statistics
Substance P and SNP caused dose-dependent increases in FBF during placebo and nicotine administration (P, Plethysmographic data were extracted from the ChartE 0.001 for all, ANOVA). Because of baseline differences, data files and forearm blood flow (FBF) was calculated for absolute FBF during substance P and SNP infusion were individual venous occlusion cuff inflations by use of a greater with nicotine administration (P,0.05, two-way template spreadsheet (Excel v5.0; Microsoft Corporation, ANOVA). However taking account of these baseline Cambridge, USA). Recordings from the first 60 s after differences, there were no significant differences in the wrist cuff inflation were not used because of the variability percentage increase in FBF with substance P or SNP in blood flow this causes [13] . The average of the last five infusion during nicotine administration (Table 2) . recordings from a 3-min interval of FBF measurement were used for analysis. The percentage change from baseline blood flow in the infused arm was calculated, as Table 1 previously described [13] , from the ratio of the infused and Compared with the non-infused arm, substance P caused 4. Discussion dose-dependent increases in plasma concentration of t-PA antigen and activity in the infused arm during nicotine and
In healthy male volunteers, short-term nicotine adminisplacebo administration (Table 3 ). The infused arm plasma tration, sufficient to increase plasma cotinine concentraconcentrations and estimated net release of t-PA antigen tions to those observed in cigarette smokers [3, 17] , was and activity were greater with nicotine administration in associated with an increase in substance-P-induced t-PA comparison to placebo ( Fig. 1 and Table 3 ). There were no release, but had no effect on endothelium-dependent significant changes in plasma PAI-1 concentrations either vasodilatation. This suggests that short-term nicotine adbetween treatment groups or before and after substance P ministration alters specific aspects of endothelial function infusion (Table 3) .
and enhances the acute endogenous fibrinolytic capacity in Table 3 Plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) concentrations during nicotine and placebo administration suggest chronic nicotine exposure depletes the free pool of brain capillary t-PA antigen [12] . The act of smoking acutely releases t-PA causing an elevation in plasma t-PA concentrations [18] that appears to be blunted in chronic cigarette smokers [19] . Indeed, chronic smoking causes a reduction in the subsequent ability to release t-PA when challenged with desmopressin [20] or venous occlusion [21] . These findings are consistent with our observations of enhanced acute t-PA release with short-term nicotine exposure and our previous findings [7] of increased basal plasma t-PA concentrations in chronic cigarette smokers but a reduced acute release of t-PA. However, further studies are now required to assess how rapidly the impairment of t-PA release reverses on cessation of cigarette smoking, and what effect nicotine supplementation has in recent ex-smokers.
The mechanisms of action of nicotine on t-PA release are unknown, but may be mediated by induction of gene expression [11] or processing of t-PA antigen at the posttranscriptional level [12] . As with cigarette smoking, there does appear to be an important difference between the effects of nicotine during acute and chronic administration [11, 12] , and whilst short-term nicotine administration appears to potentiate acute t-PA release, chronic administration may cause a reduction. This may be a consequence of the depletion of intracellular t-PA stores, desensitisation of the endothelium to further stimulation, or paradoxically a reduction in the acute storage pool due to preferential up-regulation of constitutive t-PA release. In the present investigation, short-term nicotine exposure significantly increased the capacity of the endothelium to release t-PA when challenged by substance P infusion. However, we did not observe a rise in basal plasma concentration of t-PA antigen to accompany this associated increase in acute stimulated t-PA release. This suggests that nicotine may require a more protracted period of administration or necessitate synergy with a stimulus for t-PA release, such inferred from studies of chewing tobacco or snuff users where there is systemic absorption of nicotine but not of other combustion products. These studies have found no vivo. The long-term effects of nicotine exposure, including evidence of an increased risk of myocardial infarction or the potential to cause depletion of endothelial t-PA stores, sudden cardiac death [22, 23] . Two prospective studies now needs to be assessed, particularly in recent ex-smokinvolving treatment of smokers with known cardiovascular ers.
disease using transdermal nicotine have also failed to find There are many potentially toxic chemicals in cigarette an association between nicotine use and the risk of acute smoke but there has been continued concern that nicotine cardiovascular events [24, 25] . Indeed, one study of smokmay have direct injurious effects, especially given anecdoters [25] reported more adverse events with placebo than al reports of thrombotic cardiovascular events amongst nicotine patches suggesting a protective role of nicotine. individuals regularly using NRT [8] . Although species Moreover, an experimental study of smokers with known differences exist, in vitro studies have shown that acute coronary artery disease demonstrated that nicotine supplenicotine administration increases t-PA release from bovine mentation caused a substantial reduction in exercise-inaortic endothelial cells [11] while in vivo rodent studies duced reversible myocardial perfusion defects as assessed by quantitative SPECT scanning [26] . Although there are fibrinolytic capacity in vivo. Future studies are now needed differences between epidemiological and experimental to assess the effects of long-term nicotine exposure, studies, these results suggest that nicotine in itself is not a including the potential to cause depletion of endothelial direct cause of tobacco-related cardiovascular disease.
t-PA stores, particularly in recent ex-smokers. In contrast to previous in vivo studies [27] [28] [29] , we did not find an attenuation in blood flow responses to the endothelium-dependent vasodilatation during nicotine ad
